Hims shares have roughly doubled since the start of the year, despite the FDA’s announcement last week that Novo Nordisk’s ...

周二，Morgan Stanley调整了对Hims & Hers Health, Inc. (NYSE: HIMS )的立场，将股票评级从增持下调至中性，同时将目标价从此前的42美元上调至60美元。该公司代表Craig ...

分析HIMS近期股价的急剧上升，司美格鲁肽的市场需求与短缺状况是一个重要的因素。自从相关临床研究显示司美格鲁肽在减肥方面的显著效果后，需求迅速飙升。然而，其生产受限导致的短缺使得市场上对平价替代品的需求更为迫切，HIMS自然成为这一市场机会的最大受益者。HIMS凭借其灵活的市场策略，迅速推出了该药物的平替，满足了消费者的需求，使得公司业绩和股价均获益良多。

Q4 2024 Management View CEO Andrew Dudum highlighted the company's advancements toward its vision of on-demand, personalized healthcare, noting the integration of lab testing capabilities and the ...

Morgan Stanley downgraded Hims Hers Health Inc (NYSE:HIMS) to "Equal-weight" from "Overweight" as the stock’s recent strong performance leaves limited near-term upside, despite continued business ...

Morgan Stanley cut shares of Hims & Hers Health (NYSE:HIMS – Free Report) from an overweight rating to an equal weight rating ...

Shares of Hims & Hers Health (HIMS) are down at the time of writing after Morgan Stanley, led by four-star analyst Craig Hettenbach, ...

Healthcare stock Hims and Hers (HIMS) is sharply lower today but has contrarian potential next week ahead of earnings ...

Morgan Stanley analyst Craig Hettenbach downgraded Hims & Hers to Equal Weight from Overweight with a price target of $60, up from $42. The ...

旧金山 - 知名健康与保健公司Hims & Hers Health, Inc.宣布收购新泽西州居家实验室检测机构Sigmund NJ LLC（商业名称为Trybe Labs）。这一战略性收购将为Hims & Hers平台引入居家实验室检测能力，提升个性化医疗服务。

Morgan Stanley downgraded telehealth firm Hims & Hers Health (NYSE:HIMS) to Equal Weight from Overweight on Tuesday ahead of its Q4 2024 results next week, citing the stock’s recent rally.